and reduce over-activation of microglial cells, neuroinflammation, oxidative stress, and disruption of calcium homeostasis, which lead to neuron loss
Alzheimer’s disease is now considered a world health concern; as a consequence, the National Institute on Aging—Alzheimer’s Association reclassified and updated the 1984 NINCDS-ADRDA criteria for higher specificity, sensitivity, and early identification of patients at risk of developing AD. Several criteria have been proposed for a more accurate diagnosis of AD, including clinical biomarkers, bodily fluids, and imaging studies. Despite that, the treatment of AD remains symptomatic, without alteration in the disease’s prognosis. Inhibitors to cholinesterase enzyme such as galantamine, donepezil, and rivastigmine, and NMDA antagonists such as memantine, improve memory and alertness but do not prevent progression. Several studies have shown that modification in lifestyle habits like diet and exercise can improve brain health and reduce AD without medical intervention and is considered as a first-line intervention for all AD patients. Recently, the research is focusing on targeting the pathological features of AD such as Aβ and p-tau. Future therapies such as disease-modifying treatment can alter the progression of AD by targeting the Aβ pathway, and many drugs have entered the clinical trials, like AN-1792, solanezumab, bapineuzumab, semagacestat, avagacestat, and tarenflurbil, but failed in demonstrating efficacy in the final clinical stages. Other DMTs are still under investigation, such as those targeting Aβ and tau pathologies, such as aducanumab, gantenerumab, crenezumab, tideglusib, lithium, and others. Other promising compounds called chaperones like heat shock proteins and vacuolar sorting protein 35 (VPS35) function by assisting other proteins to function normally and to arrive at their destination in the cell safely, and therefore can be used as a treatment for neurodegenerative diseases. Moreover, the natural extracts used in folk Chinese medicine showed great potential in treating AD by acting on several mechanisms’ pathways. In conclusion, the success of AD treatment depends on its early administration and patient monitoring for disease progression using biomarkers diagnosis. Future therapies that target tau pathology and the use of combination therapy may have a potential to slow the progression of AD pathology. Designing a potent, selective, and effective drug is urgently needed to treat patients with AD and those at risk for developing the disease.
Literature survey and first draft writing were done by Z.B., and final draft, including the revisions, were accomplished by R.K. All authors have read and agreed to the published version of the manuscript.
This research received no external funding.
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Announcing the launch of mini reviews.
Concise overview articles of key topics in neurodegeneration, which can be read wherever you are, whenever suits you.
Find out more here .
Alzheimer's Research & Therapy presents a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series here .
Authors: Aishwarya Pradeep, Sheelakumari Raghavan, Scott A. Przybelski, Gregory M. Preboske, Christopher G. Schwarz, Val J. Lowe, David S. Knopman, Ronald C. Petersen, Clifford R. Jack Jr, Jonathan Graff-Radford, Petrice M. Cogswell and Prashanthi Vemuri
Authors: Yihao Guo, Liangdong Zhou, Yi Li, Gloria C. Chiang, Tao Liu, Huijuan Chen, Weiyuan Huang, Mony J. de Leon, Yi Wang and Feng Chen
Authors: Matthew D. Howe, Karysa J. Britton, Hannah E. Joyce, William Menard, Sheina Emrani, Zachary J. Kunicki, Melanie A. Faust, Brittany C. Dawson, Meghan C. Riddle, Edward D. Huey, Shorena Janelidze, Oskar Hansson and Stephen P. Salloway
Authors: Lucia Mencarelli, Mario Torso, Ilaria Borghi, Martina Assogna, Valentina Pezzopane, Sonia Bonnì, Francesco Di Lorenzo, Emiliano Santarnecchi, Federico Giove, Alessandro Martorana, Marco Bozzali, Gerard R. Ridgway, Steven A. Chance and Giacomo Koch
Authors: Line Damsgaard, Janet Janbek, Thomas Munk Laursen, Karsten Vestergaard, Hanne Gottrup, Christina Jensen-Dahm and Gunhild Waldemar
Most recent articles RSS
View all articles
Authors: Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao
Authors: Sergi Martinez-Ramirez, Steven M Greenberg and Anand Viswanathan
Authors: Robert Vassar
Authors: Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer and Jeffrey L. Cummings
The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14 :70
Authors: Jeffrey L Cummings, Travis Morstorf and Kate Zhong
Most accessed articles RSS
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
10 Years of Alzheimer's Research & Therapy
Subject Cognitive Decline
Your browser needs to have JavaScript enabled to view this timeline
Failed to load RSS feed.
Citation Impact 2023 Journal Impact Factor: 7.9 5-year Journal Impact Factor: 8.3 Source Normalized Impact per Paper (SNIP): 1.687 SCImago Journal Rank (SJR): 2.608 Speed 2023 Submission to first editorial decision (median days): 11 Submission to acceptance (median days): 152 Usage 2023 Downloads: 1,914,774 Altmetric mentions: 2,982
ISSN: 1758-9193
By The Mount Sinai Hospital / Mount Sinai School of Medicine June 1, 2024
Mount Sinai researchers have discovered a potential new method to treat Alzheimer’s by targeting the plexin-B1 protein to improve plaque clearance in the brain, opening avenues for future therapeutic strategies. Credit: SciTechDaily.com
Researchers at the Icahn School of Medicine at Mount Sinai have achieved a major breakthrough in Alzheimer’s disease research. Their study identifies a promising method that could potentially slow or even stop the progression of the disease. Focusing on the role of reactive astrocytes and the plexin-B1 protein in Alzheimer’s disease, the research offers vital insights into how brain cells communicate. This opens up new avenues for innovative treatment approaches. The findings were published on May 27 in the journal Nature Neuroscience .
This groundbreaking work is centered on the manipulation of the plexin-B1 protein to enhance the brain’s ability to clear amyloid plaques, a hallmark of Alzheimer’s disease. Reactive astrocytes, a type of brain cell that becomes activated in response to injury or disease, were found to play a crucial role in this process. They help control the spacing around amyloid plaques, affecting how other brain cells can access and clear these harmful deposits.
“Our findings offer a promising path for developing new treatments by improving how cells interact with these harmful plaques,” said Roland Friedel, PhD, Associate Professor of Neuroscience, and Neurosurgery, at Icahn Mount Sinai and a senior author of the study. The research was driven by the analysis of complex data comparing healthy individuals to those with Alzheimer’s, aiming to understand the disease’s molecular and cellular foundations.
Icahn Mount Sinai researchers find PLXNB1, a hub gene predicted to drive a gene subnetwork causally linked to human AD, is upregulated in reactive astrocytes surrounding amyloid plaques. Credit: Bin Zhang, PhD, Icahn Mount Sinai
Hongyan Zou, PhD, Professor of Neurosurgery, and Neuroscience, at Icahn Mount Sinai and one of the study’s lead authors, highlighted the broader implications of their findings: “Our study opens new pathways for Alzheimer’s research, emphasizing the importance of cellular interactions in developing neurodegenerative disease treatments.”
One of the study’s most significant achievements is its validation of multiscale gene network models of Alzheimer’s disease. “This study not only confirms one of the most important predictions from our gene network models but also significantly advances our understanding of Alzheimer’s. It lays a solid foundation for developing novel therapeutics targeting such highly predictive network models,” said Bin Zhang, PhD, Willard T.C. Johnson Research Professor of Neurogenetics at Icahn Mount Sinai and one of the study’s lead authors. By demonstrating the critical role of plexin-B1 in Alzheimer’s disease, the research underscores the potential of targeted therapies to disrupt the disease’s progression.
The research team emphasizes that while their findings mark a significant advance in the fight against Alzheimer’s, more research is needed to translate these discoveries into treatments for human patients.
“Our ultimate goal is to develop treatments that can prevent or slow down Alzheimer’s progression,” Dr. Zhang added, outlining the team’s commitment to further exploring the therapeutic potential of plexin-B1.
Reference: “Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease” by Yong Huang, Minghui Wang, Haofei Ni, Jinglong Zhang, Aiqun Li, Bin Hu, Chrystian Junqueira Alves, Shalaka Wahane, Mitzy Rios de Anda, Lap Ho, Yuhuan Li, Sangjo Kang, Ryan Neff, Ana Kostic, Joseph D. Buxbaum, John F. Crary, Kristen J. Brennand, Bin Zhang, Hongyan Zou and Roland H. Friedel, 27 May 2024, Nature Neuroscience . DOI: 10.1038/s41593-024-01664-w
This study is supported by the NIH National Institute on Aging (NIA) grants U01AG046170 and RF1AG057440 and is part of the NIA-led Accelerating Medicines Partnership – Alzheimer’s Disease (AMP-AD) Target Discovery and Preclinical Validation program. This public-private partnership aims to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention.
Be the first to comment on "alzheimer’s breakthrough: researchers discover novel way to potentially halt disease progression", leave a comment cancel reply.
Email address is optional. If provided, your email will not be published or shared.
Save my name, email, and website in this browser for the next time I comment.
Here's how you know
Official websites use .gov A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.
Alzheimer’s disease and related dementias are a series of complex brain disorders that affect millions of Americans and many more people worldwide. These disorders have an enormous impact on individuals and their families, long-term care facilities, health care providers, health care systems and infrastructure, and the communities in which we all live. As the economic, social, and personal costs of these diseases climb, the research community is working to discover solutions that will improve the lives of those with dementia, their caregivers, and their communities.
The federal government’s Alzheimer’s and related dementias research strategy focuses on engaging a cross-disciplinary team of geneticists, epidemiologists, gerontologists, behavioral scientists, disease and structural biologists, pharmacologists, clinical researchers, and others to bring the greatest and most diverse expertise to the field. This includes training new generations of researchers and clinician-scientists and engaging in innovative partnerships with private industry, nonprofit groups, and more to foster collaboration and broaden access to research resources and data.
Critically, the government’s research strategy includes the search to find treatment and prevention strategies, as well as interventions, services, and supports to improve quality of life for those already living with these diseases and their families.
The National Institutes of Health (NIH) is made up of Institutes, Centers, and Offices that conduct and fund research into all aspects of human health. The National Institute on Aging (NIA) leads NIH’s efforts in clinical, behavioral, and social research in Alzheimer’s and related dementias through efforts aimed at finding ways to treat and ultimately prevent the disorder. NIA collaborates closely with the National Institute of Neurological Disorders and Stroke (NINDS), which manages a research portfolio targeting Alzheimer’s-related dementias. While some of this research takes place in NIH laboratories, the vast majority of NIH support is provided through a competitive grants process to institutions and small businesses across the country. Other federal agencies support a range of activities focused on public health and community programs.
As the nation’s biomedical research agency, NIH supports research ranging from basic biology to drug development and from clinical studies to evaluating public health outcomes. Within the past several decades, researchers have made great strides toward better understanding what causes Alzheimer’s and related dementias and discovering approaches that may prevent, diagnose, and treat them. Some highlights of these efforts include:
Even with the progress that we’ve made, there’s still a lot of work to do before we can find treatment and prevention strategies for the millions of people affected by Alzheimer’s and related dementias. These devastating diseases are highly complex conditions caused by an interplay of genetic, lifestyle, and environmental factors. They usually develop gradually — changes in the brain take place over years and even decades, long before the first symptoms appear. This complexity presents challenges to the discovery and development of new drugs and other prevention and treatment approaches.
Researchers believe Alzheimer’s and related dementias will likely require multiple treatments customized to individuals. We also know that as the older population continues to grow — aging remains the most important risk factor for dementia — we will see increased numbers of people living with these diseases. That’s why thousands of researchers around the country are working on this issue.
NIH takes a collaborative, methodical approach to reviewing progress, identifying gaps, and setting the future agenda for research into Alzheimer’s and related dementias. NIH funding in this area is guided by gaps and opportunities identified in research summits , which alternate yearly to focus on Alzheimer’s, Alzheimer’s-related dementias, or dementia care and services. Smaller, focused workshops are held more frequently on specific aspects of this research.
NIH outlines its Alzheimer’s research efforts in the NIH AD/ADRD Research Implementation Milestones , a research framework detailing specific steps and success criteria toward achieving the goals of the National Plan to Address Alzheimer’s Disease . The milestones also showcase funding initiatives, accomplishments, and highlights of progress toward accomplishing the National Plan goals.
NIH’s research progress is highlighted in the annual Alzheimer’s and related dementias professional judgment budget , which is submitted to Congress each year.
Each year NIH submits a professional judgment budget that estimates the additional funding needed to advance NIH-supported research into the treatment and prevention of Alzheimer’s and related dementias. The report also summarizes progress and promising research opportunities. Only two other areas of biomedical research — cancer and HIV/AIDS — follow a similar process designed to accelerate research discovery. This approach is often referred to as a “bypass budget” because of its direct transmission to the President and then to Congress without modification through the traditional federal budget process.
No major advance in Alzheimer’s and related dementias treatment, prevention, or care will be possible without robust clinical research. Clinical research includes studies that involve people so scientists can learn more about disease progression, how behavior and lifestyle factors may affect health, and the safety and effectiveness of an intervention. Advances made through clinical research rely on the volunteers who participate in these types of studies. NIA is working on multiple initiatives to enhance recruitment and retention of diverse populations in clinical research. View some of those resources below.
NIA-funded clinical research includes both observational studies through which researchers gather important information, and clinical trials in which researchers test interventions to treat or prevent disease, improve care and caregiver support, and enhance quality of life for people living with dementia. NIA is currently funding more than 400 active clinical trials .
NIA also funds more than 30 Alzheimer’s Disease Research Centers across the country. Scientists at these centers conduct clinical research to improve diagnosis and care for people with dementia and their families, and to find a treatment or increase prevention.
You could help discover new ways to treat and prevent Alzheimer’s and related dementias.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Explore the resources on this website and linked below to find more information from federal government agencies.
View professional judgment budgets for Alzheimer’s and related dementias from NIH, including yearly updates on research progress.
Browse this database to learn more about research implementation plans and progress toward the goal of treating or preventing Alzheimer’s and related dementias.
Search this repository of resources to support the recruitment and retention of participants into clinical trials and studies on Alzheimer’s disease and related dementias.
Learn about the data sharing policies, considerations, resources, and guidance available to support researchers in safely and efficiently sharing data from their studies.
Visit IADRP to search a database of categorized research across public and private sources.
Learn about NIA's efforts toward the National Plan and NIH annual summits that shape research priorities.
View a list of all active NIA-funded clinical trials, including drug trials, intervention studies, and care and caregiver interventions.
Search for NIA-supported clinical research tools, datasets, samples, visualization tools, and more for Alzheimer’s and related dementias research.
Read the National Strategy for Recruitment and Participation in Alzheimer’s and Related Dementias Research and get resources to support study recruitment.
Read about the National Institute of Neurological Disorders and Stroke’s research into Alzheimer’s disease-related dementias.
Search NIH-funded research in Alzheimer’s and related dementias.
The Alzheimer’s & related Dementias Education & Referral (ADEAR) Center is a service of the National Institute on Aging at the National Institutes of Health. Call 800-438-4380 or email [email protected] to talk with an information specialist.
Last updated: July 9, 2024
This content is provided by the National Institute on Aging (NIA), part of the National Institutes of Health. NIA scientists and other experts review this content to ensure it is accurate and up to date.
alzheimers.gov
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health
Masks strongly recommended but not required in maryland, starting immediately.
Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more .
Research aims to uncover the mysteries of alzheimer’s disease.
Physicians often detect early warning signs of dementia in their aging patients from the stories shared by a patient’s family members. They learn about situations that are out of character, such as paying a bill multiple times, misplacing keys and repeating stories. Often a patient has become more irritable and anxious.
When the clinical examination also suggests that a longtime patient’s behavior or disposition has changed, the next step is to rule out possible causes such as medication issues, poor sleep or traumatic life events, according to Esther Oh , co-director of the Johns Hopkins Memory and Alzheimer’s Treatment Center.
“When there’s clearly some functional impairment going on, I try to figure out why,” she says. “How older patients experience cognitive problems is complex.”
If physicians suspect a patient may have mild cognitive impairment due to Alzheimer’s disease or a related brain disease, they can order a variety of labs including blood tests, MRIs and CT scans, and may refer the patient to Oh and her colleagues in psychiatry, geriatrics or neurology at the Memory and Alzheimer’s Treatment Center.
There, patients can receive individualized treatment based on their needs, including medications targeting memory and cognition and treatments for mood, behavioral and sleep changes. Additionally, patients, caregivers and family members can get guidance and support that helps improve their quality of life, plan for the future and manage inevitable crises.
Much is still unknown about the disease. At this time, there’s no cure for Alzheimer’s, no proven way of slowing down its progression and no treatment available to reverse the deterioration that occurs in the brain.
Best practices for managing the disease include physical and social activity, healthy lifestyle and diet, and a well-structured environment. Older adults who engage in these behaviors appear to have less risk of cognitive and functional decline.
While the diagnosis is grim, Johns Hopkins clinicians and researchers are broadening Alzheimer’s and dementia research and expanding treatment options in a number of ways: searching for biological markers (biomarkers) that could predict Alzheimer’s; determining how to target certain proteins that are present in the brains of patients with the disease; defining the different kinds of Alzheimer’s to tailor future treatment and research; developing new drugs; and piloting a home-based care program.
Dementia is a general term that refers to memory loss and decline of other cognitive abilities that limit independence in day-to-day function. Alzheimer’s is the most common brain disease that causes dementia among older adults, accounting for 60%–80% of cases. It affects an estimated one in nine people age 65 and older — 6.2 million Americans. This number is projected to grow to 12.7 million by 2050, according to the Alzheimer’s Association.
Almost two-thirds of the cases are in women, and people of color are at a higher risk of developing Alzheimer’s.
Alzheimer’s is a progressive, neurodegenerative disease that occurs when nerve cells in the brain die. It affects memory, thinking and behavior. But, unlike other forms of dementia, it does not affect patients’ motor function until late stages of the disease.
Alzheimer’s experts think individuals may experience different versions of the disease.
“It’s probably not one kind of Alzheimer’s disease, it’s probably many,” says psychiatrist Paul Rosenberg , co-director of the Johns Hopkins Memory and Alzheimer’s Treatment Center. “What we want to do is find the subtypes so we can find better treatments.”
Cancer treatment, for example, is specific to the kind and subtype of cancer. Breast cancer is treated differently from colon cancer, and within breast cancer, different subtypes mean different treatments. This is the direction in which Johns Hopkins researchers hope to move Alzheimer’s treatment.
Rosenberg and his colleagues, including Memory and Alzheimer’s Treatment Center director Kostas Lyketsos , are crunching data in the Richman Family Precision Medicine Center of Excellence in Alzheimer’s Disease to do just that. The goal is to find characteristics that can allow physicians to predict which patients will develop Alzheimer’s, as well as determine what clinical data is necessary to differentiate subtypes of the disease.
The Precision Medicine Center’s patient registry includes more than 130,000 medical records that researchers hope can help define clinical subgroups of patients with dementia, determine when symptoms first develop and when diagnoses occur, among other factors. Additionally, center researchers are developing a collection of unique blood biomarkers that could help target future treatments to subgroups of patients.
Other projects include:
Other Johns Hopkins researchers are testing a drug that has the potential to slow the progression of Alzheimer’s. Marilyn Albert , director of the Johns Hopkins Alzheimer’s Disease Research Center , Michela Gallagher , a professor of neuroscience at the Johns Hopkins University School of Medicine, and Arnold Bakker , director of the Johns Hopkins Psychiatric Neuroimaging Core , hope to receive FDA approval for the drug for patients in the earliest stages of the disease.
The drug targets two proteins: tau, which serves many functions in healthy neurons but can accumulate into tangles in cells, and amyloid, which forms plaques between cells. Gallagher theorized that periods of hyperactivity in the brain, such as seizures, push those proteins around the brain, spreading more tangles and plaques. She identified a compound, levetiracetam, that calms these hyperactive periods and is now approved by the FDA to treat seizures in patients with epilepsy when used with other medications. She and Albert are testing a time-release capsule version of levetiracetam taken at breakfast by patients in early stages of the disease.
The study , sponsored by AgeneBio , involves more than 164 people taking the drug for 78 weeks at 27 research sites across the country. Preliminary results are expected in fall 2022.
In addition to Albert and Gallagher’s drug, referred to as AGB101, there are more than 100 other Alzheimer’s drugs being tested at Johns Hopkins and elsewhere, according to the Alzheimer’s Association.
As researchers wrestle with how to catch the disease in its early stages, the question of whether to do universal screening for cognitive impairment remains. Such screening is required as part of the Medicare Annual Wellness visit, initiated in 2011 as part of the Affordable Care Act. While primary care providers must perform this screening for Medicare patients, specialists at Johns Hopkins believe this kind of test can be useful in more targeted ways.
“There could be a place for targeted universal screening, but we have to be very careful,” Oh says. “The question remains, what are you going to do with that information?”
In some scenarios, screening may be appropriate, she says. For example, a patient undergoing surgery who has possible cognitive impairment could be screened in order to make sure they understand the procedure as well as post-op instructions. It could help providers manage possible complications, such as delirium after surgery, which occurs more commonly in individuals with dementia.
The Alzheimer’s Association recommends evaluation for people with memory concerns or cognitive complaints as well as for those with non-memory triggers, including personality change, depression, deterioration of chronic disease without explanation, and falls or balance issues. It is also recommended if a family member or loved one reports cognitive impairment.
Like Oh, Paul Rosenberg and Kostas Lyketsos don’t see a role for universal screening as there’s no demonstrated benefit from it.
“Until we have a safe and effective therapy that people can afford, it is just not ethical to do the tests,” Rosenberg says.
Alzheimer’s disease: frustration and hope.
While Johns Hopkins clinicians help patients with Alzheimer's disease maximize quality of life, researchers are gaining insights that could lead to better treatment.
New research suggests that if you are caring for a spouse with Alzheimer’s, you have a higher risk of developing the disease yourself.
Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refers to the most common forms of dementia. Dementia likely affects more than 6 million people in the U.S. and more than 55 million people worldwide . Currently, there are no known treatments to prevent or stop the progression of dementia. The toll on individuals, caregivers and society is enormous and will increase as the population ages unless effective interventions are developed. NINDS collaborates with NIH ’s National Institute on Aging ( NIA ), the lead NIH Institute for Alzheimer’s disease (AD) research and for NIH's response to the National Plan to Address Alzheimer’s Disease , to establish research priorities and fund biomedical research to decrease the burden of dementia on individuals, families, and communities.
While AD is the most common dementia diagnosis, ADRDs share many cognitive and pathological features with and can be difficult to distinguish from AD. In fact, more often than not, patients with a clinical diagnosis of Alzheimer’s disease have different mixtures of brain pathologies, complicating both the diagnosis, as well as treatment. A special video testimonial to raise awareness of the disease burden on patients with AD/ADRD and their caregivers titled “Voices of AD/ADRD” was presented at the NINDS ADRD Summit 2022 , and can be viewed here: Voices of AD/ADRD
In the National Plan to Address Alzheimer’s Disease , ADRDs include: Frontotemporal degeneration (FTD) Lewy body dementia (LBD) Vascular contributions to cognitive impairment and dementia (VCID) Multiple-Etiology Dementias (MED)
NINDS and NIA continue to partner in AD/ADRD research planning and implementation, and we urge the research community to join in our efforts to accelerate scientific progress toward reducing the enormous burden and cost of dementia.
No RFA is needed to apply!! NINDS special AD/ADRD payline applies to investigator- Initiated research applications to the NIH Parent R01 and the NINDS R21 ( PA-21-219 ) NINDS AD/ADRD Payline Information
Currently active , basic disease mechanisms.
Interaction Between Environmental Factors and Lewy Body Dementia (R01 - Clinical Trial Not Allowed) (PAR-24-249) Due dates: October 04, 2024 Contact PO: David Jett
Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed) (PAR-24-234) Due dates: October 04, 2024 Contact PO : George Umanah
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-24-148) Due dates: June 04, 2024 and October 04, 2024 ; Contact PO: Linda McGavern
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-24-147) Due dates: June 04, 2024 and October 04, 2024 ; Contact PO: Linda McGavern
Mechanisms of Cognitive Fluctuations in ADRD Populations (R01 - Clinical Trial Optional) (RFA-NS-25-014) Due date: June 24, 2024 ; Contact PO: Debra Babcock
Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R01 - Clinical Trial Not Allowed) (PAR-24-196) Due date: October 04, 2024 ; Contact PO: Roderick Corriveau
Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) after anti-Aβ immunotherapy (R01 - Clinical Trial Not Allowed) (PAR-24-198) Due date: October 04, 2024 ; Contact PO: Francesca Bosetti
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) (PAR-24-203) Due date: October 04, 2024 ; Contact PO: William P. Daley
Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed) ( RFA-NS-25-013) Due date: October 04, 2024 ; Contact POs: Richard T. Benson, Rebecca Hommer and Carolina Mendoza-Puccini Email: [email protected]
Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required) (RFA-NS-25-010) Due date: January 24, 2025 ; Contact PO: Rebecca Hommer
NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award (K99/R00 Independent Clinical Trial Not Allowed) (PAR-24-213) Due date: NIH Standard due dates ; Contact PO: Amber McCartney
NINDS Alzheimer’s Disease-Related Dementias (ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed) ( PAR-24-212 ) Due date: NIH Standard due dates ; Contact PO: Amelie Gubitz, and Lauren Ullrich Email: [email protected]
Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS ADRD Awardees ( NOT-NS-24-071) Expiration date: February 15, 2027 ; Contact PO: Amber McCartney
Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed) (RFA-NS-25-011) Due date: November 08, 2024 ; Contact PO: Pascal Laeng
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (Small Business Innovation Research; R43/R44 Clinical Trial Optional) (PAR-22-196) Due date: NIH Standard due dates ; Contact PO: Annette Gilchrist
Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (Small Business Technology Transfer; R41/R42 Clinical Trial Optional) (PAR-22-197) Due date: NIH Standard due dates ; Contact PO: Annette Gilchrist
Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) (RFA-NS-24-032) Due dates: June 20, 2024 and October 21, 2024 ; Contact POs: Linda McGavern and Frank Shewmaker
We are excited to share with you the research concepts approved by NINDS Council. Please note that this page will be periodically updated with links when funding opportunities are published. These are also announced via our email listserv (to join the NINDS AD/ADRD listserv, please email [email protected] ).
Please note that an approved concept listed below does not necessarily indicate an award mechanism or funding allocation is imminent or will happen. The NOFO is only official when published in the NIH Guide .
Optimization of Genome Editing Therapeutics for ADRDs- This initiative will support early translational research focused on somatic cell genome editing for Alzheimer's Disease Related Dementias (ADRDs). It is expected that these studies will address the feasibility of using genome editing for therapy development for ADRDs. Contact PO: Timothy LaVaute
Integrative Multiomics Profiling for Lewy Body Dementia- This initiative is designed to support research to conduct genetic and molecular characterization of LBD. This may include whole genome sequencing, longitudinal bulk-transcriptomics, longitudinal matched plasma, and cerebrospinal fluid (CSF) proteomic analysis, and post-mortem single-cell RNA sequencing, which will be generated and paired with harmonized longitudinal clinical data. Contact PO: Christine Swanson-Fischer
ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment- This initiative is to support research that aim to by determine how exposures at innervated human surfaces affect ADRD disease mechanisms and phenotypic outcomes. These exposures include toxins and toxic chemicals, viral and other pathogens, and other environmental exposures. Contact PO: David Jett
Including ADRD Biomarker Measures and APOE Genotype Status to ADRD Human Subjects Research Studies- This initiative is to provide funding to existing AD/ADRD cohort studies to support the inclusion/addition of ADRD fluid-based biomarker measures and APOE genotype status when they are not already utilized in the original study. Contact PO: Amber McCartney
IND -enabling Studies and Clinical Trials for Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias - This initiative support Investigational New Drug (IND) enabling studies for the preparation and submission of an IND for a genome editing therapeutics for ADRD, and optional small delayed-onset first in human Phase I clinical trial. Contact PO: Timothy LaVaute
VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed) ( RFA-NS-24-027)
Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed) (PAR-23-140)
Role of Environmental Stress in the Health Inequities of Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) ( RFA-NS-24-024)
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (PAR-23-211)
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD, and other ADRDs (R01 - Clinical Trial Not Allowed) (PAR-23-212)
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed) (PAR-23-214)
Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required) (RFA-NS-24-013)
Tools and Resources to Understand the Vascular Pathophysiology of in vivo Neuroimaging Findings in ARIA (U24 - Clinical Trials Not Allowed) (RFA-NS-24-034) Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials (U19 Clinical Trial Optional) (RFA-NS-24-001)
Validating digital health technologies for monitoring biomarkers in ADRD clinical trials (R61/R33 - Clinical Trials Optional) (RFA-NS-24-026)
Assessment of TBI-related ADRD Pathology Related to Cognitive Impairment and Dementia Outcomes (U01 - Clinical Trial Not Allowed) (RFA-NS-24-003)
Administrative Supplements to Promote Diversity for NINDS AD/ADRD Awardees (NOT-NS-21-047)
NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed) ( PAR-23-113)
Simultaneous and Synergistic Multi-Target Validation for Alzheimer’s Disease-Related Dementias (R61/R33 Clinical Trial not allowed) ( PAR-23-195)
Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) ( RFA-NS-24-010)
Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed) (RFA-NS-24-009)
Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional) ( RFA-NS-19-014)
Development & Characterization of Experimental models of post-TBI ADRD (R01 - Clinical Trial Not Allowed) (PAR-23-218)
Development and Validation of Models for ADRD (R61/R33 - Clinical Trial Not Allowed) (PAR-23-154)
NINDS-led ADRD summits represent a continuous decade long planning effort. ADRD summits occur every three years and respond to the National Plan to Address Alzheimer’s Disease (“National Plan”) that was released in 2012 and updated annually. These Summits set national research recommendations with timelines that reflect critical scientific priorities for research on ADRD. During each ADRD Summit planning process, the established prioritized recommendations are updated, and developed further, under the leadership of the ADRD Summit Steering Committee, which includes a Working Group of the NANDS Council. The Committee solicits input from nationally and internationally recognized dementia-science experts, as well as public and private stakeholders. The resulting recommendations guide ADRD research for the next several years. Links to NANDS Council-approved ADRD Summit Reports are provided below.
ADRD Summit 2022 FACA Report; (pdf, 3804 KB) ADRD Summit 2022 Research Milestones and Success Criteria (pdf, 512 KB)
ADRD Summit 2019 FACA Report (pdf, 2131 KB) ; ADRD Summit 2019 Research Milestones and Success Criteria
ADRD Summit 2016 FACA Report (pdf, 922 KB) ; ADRD Summit 2016 Research Milestones and Success Criteria ; Proceedings Article
ADRD Summit 2013 FACA Report (pdf, 980 KB) ; ADRD Summit 2013 Research Milestones and Success Criteria ; Proceedings Article
Rod Corriveau | Program Director and ADRD Lead [email protected]
Sara Dodson | Senior Health Science Policy Analyst [email protected]
Erin Bryant | Office of Neuroscience Communications & Engagement (ONCE) [email protected]
Amber McCartney | Scientific Project Manager [email protected]
Arvind Shukla | Health Program Specialist [email protected]
Herson Rene Astacio Cuevas | Health Program Specialist [email protected]
Kiara Bates | Program Specialist [email protected]
Related Topics AD+ADRD Research Implementation Milestones database The AD+ADRD Research Implementation Milestones database is a research framework detailing specific steps and success criteria towards achieving the goal of the National Plan to Address Alzheimer's Disease : to treat and prevent AD and ADRDs by 2025. This database includes research milestones and responsive activities for the NIH triennial AD, ADRD, and Dementia Care, Services and Supports research summits. International Alzheimer's and Related Dementias Research Portfolio IADRP reports categories of funded research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's and Related Dementias Research Ontology (CADRO)
Research/Disease Areas* | FY 2020 | FY 2021 | FY 2022 | FY 2023 (Estimated) | FY 2024 (Estimated) |
---|---|---|---|---|---|
Alzheimer's Disease Including Alzheimer's Disease Related Dementias (AD/ADRD) | $2,869 | $3,251 | $3,514 | $3,749 | $3,767 |
Alzheimer's Disease | $2,683 | $3,059 | $3,314 | $3,502 | $3,515 |
Frontotemporal Dementia | $166 | $164 | $169 | $174 | $177 |
Lewy Body Dementia | $84 | $113 | $118 | $124 | $124 |
Vascular Contributions to Cognitive Impairment and Dementia | $362 | $455 | $445 | $461 | $464 |
*Dollars in millions and rounded To learn more about NIH Investment in AD/ADRD, please visit the Categorical Spending site and enter "Alzheimer's Disease Including Alzheimer's Disease Related Dementias".
Holtzman, Chen recognized for exceptional Alzheimer’s research
Washington University School of Medicine in St. Louis faculty members David M. Holtzman, MD , the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology, and Xiaoying Chen , an instructor in neurology, were awarded the inaugural Jeffrey L. Morby Prize from the Cure Alzheimer’s Fund, a nonprofit dedicated to supporting the most promising research to prevent, slow or reverse Alzheimer’s disease.
The prize recognizes the senior and first authors of a recent scientific publication that transforms the fundamental understanding of Alzheimer’s disease and opens new paths to translate scientific results into effective ways to prevent, diagnose or treat the neurodegenerative condition.
Read more on the School of Medicine website .
Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments. We also cannot address individual medical concerns or provide medical advice in this forum.
Announcements.
WashU Night at the Ballpark tickets on sale
WUPD active shooter training drill Thursday
Parking shares latest update
Office of Technology Management to mentor Mizzou on commercialization
Vanyo awarded protein research training
Leah Rae Czerniewski, biomedical engineering doctoral student, 34
Ruth Levinsohn Siteman, philanthropist, 92
Stan H. Braude, professor of practice in Arts & Sciences, 62
Physician-scientists receive Scholar-Innovator award
Tikhonov wins NSF CAREER award
Building ‘time-traveling’ quantum sensors
Washington people.
Amy Zhou
Sadie Williams Clayton
Caitlyn Collins
Who Knew WashU? 1.27.21
Who Knew WashU? 1.13.21
Who Knew WashU? 12.9.20
Ten million new cases of dementia are diagnosed each year but the presence of different dementia forms and overlapping symptoms can complicate diagnosis and delivery of effective treatments. Now researchers from Boston University have developed an AI tool that can diagnose ten different types of dementia such as vascular dementia, Lewy body dementia, and frontotemporal dementia, even if they co-occur.
The researchers created a multimodal Machine Learning (ML) framework that accurately identifies specific pathologies causing dementia using commonly collected clinical data, such as demographic information, patient- and family-level medical history, medication use, neurological and neuropsychological exam scores and neuroimaging data such as MRI scans.These findings appear online in Nature Medicine .
"Our generative AI tool enables differential dementia diagnosis using routinely collected clinical data, showing its potential as a scalable diagnostic tool for AD and related dementias," says corresponding author Vijaya B. Kolachalama, PhD, FAHA, associate professor of medicine at Boston University Chobanian & Avedisian School of Medicine. "The ability to generate diagnosis with routine clinical data is becoming increasingly important given the significant challenges in accessing gold-standard testing, not only in remote and economically developing regions and in urban healthcare centers," adds Kolachalama who also is an associate professor of computer science, affiliate faculty of Hariri Institute for Computing, and a founding member of the Faculty of Computing & Data Sciences at Boston University.
In the study, the multimodal ML framework was trained on data from more than 50,000 individuals from nine different global datasets. The model achieved an area under the receiver operating characteristic (ROC) curve of 0.96 in differentiating the dementia types. The ROC score can range from 0 to 1. A score of 0.5 indicates random guessing, and a score of 1 indicates perfect performance.
The team also compared the performance of neurologists and neuro-radiologists working alone versus with the AI tool, and found that AI can boost the accuracy of neurologists by more than 26% across all 10 dementia types. Using 100 randomly selected cases, 12 neurologists were asked to make a diagnosis and provide a confidence score between 0 to 100. This confidence score was then averaged with the probability score obtained by the AI tool to obtain an AI-augmented neurologist score.
"There aren't enough neurology experts around the world, and the number of patients needing their help is growing quickly. This mismatch is putting a big strain on the healthcare system. We believe AI can help by identifying these disorders early and assisting doctors in managing their patients more effectively, preventing the diseases from getting worse," says Kolachalama.
With dementia cases set to double in the next 20 years, the researchers hope that this AI tool can provide accurate differential diagnosis and support the increased demand in targeted therapeutic interventions for dementia.
This project was supported by grants from the Karen Toffler Charitable Trust, National Institute on Aging's Artificial Intelligence and Technology Collaboratories (P30-AG073014), the American Heart Association (20SFRN35460031), Gates Ventures, and the National Institutes of Health (R01-HL159620, R21-CA253498, R43-DK134273, RF1-AG062109, U19-AG068753, P20-GM130447, K23-NS075097, P50-AG047366, and R01-NS115114)
Story Source:
Materials provided by Boston University School of Medicine . Note: Content may be edited for style and length.
Journal Reference :
Cite This Page :
Strange & offbeat.
About the university, research at cambridge.
We’ve created a tool which is much more sensitive than current approaches at predicting whether someone will progress from mild symptoms to Alzheimer’s Zoe Kourtzi
The team say this new approach could reduce the need for invasive and costly diagnostic tests while improving treatment outcomes early when interventions such as lifestyle changes or new medicines may have a chance to work best.
Dementia poses a significant global healthcare challenge, affecting over 55 million people worldwide at an estimated annual cost of $820 billion. The number of cases is expected to almost treble over the next 50 years.
The main cause of dementia is Alzheimer’s disease, which accounts for 60-80% of cases. Early detection is crucial as this is when treatments are likely to be most effective, yet early dementia diagnosis and prognosis may not be accurate without the use of invasive or expensive tests such as positron emission tomography (PET) scans or lumbar puncture, which are not available in all memory clinics. As a result, up to a third of patients may be misdiagnosed and others diagnosed too late for treatment to be effective.
A team led by scientists from the Department of Psychology at the University of Cambridge has developed a machine learning model able to predict whether and how fast an individual with mild memory and thinking problems will progress to developing Alzheimer’s disease. In research published today in eClinical Medicine , they show that it is more accurate than current clinical diagnostic tools.
To build their model, the researchers used routinely-collected, non-invasive, and low-cost patient data – cognitive tests and structural MRI scans showing grey matter atrophy – from over 400 individuals who were part of a research cohort in the USA.
They then tested the model using real-world patient data from a further 600 participants from the US cohort and – importantly – longitudinal data from 900 people from memory clinics in the UK and Singapore.
The algorithm was able to distinguish between people with stable mild cognitive impairment and those who progressed to Alzheimer’s disease within a three-year period. It was able to correctly identify individuals who went on to develop Alzheimer’s in 82% of cases and correctly identify those who didn’t in 81% of cases from cognitive tests and an MRI scan alone.
The algorithm was around three times more accurate at predicting the progression to Alzheimer’s than the current standard of care; that is, standard clinical markers (such as grey matter atrophy or cognitive scores) or clinical diagnosis. This shows that the model could significantly reduce misdiagnosis.
The model also allowed the researchers to stratify people with Alzheimer’s disease using data from each person’s first visit at the memory clinic into three groups: those whose symptoms would remain stable (around 50% of participants), those who would progress to Alzheimer’s slowly (around 35%) and those who would progress more rapidly (the remaining 15%). These predictions were validated when looking at follow-up data over 6 years. This is important as it could help identify those people at an early enough stage that they may benefit from new treatments, while also identifying those people who need close monitoring as their condition is likely to deteriorate rapidly.
Importantly, those 50% of people who have symptoms such as memory loss but remain stable, would be better directed to a different clinical pathway as their symptoms may be due to other causes rather than dementia, such as anxiety or depression.
Senior author Professor Zoe Kourtzi from the Department of Psychology at the University of Cambridge said: “We’ve created a tool which, despite using only data from cognitive tests and MRI scans, is much more sensitive than current approaches at predicting whether someone will progress from mild symptoms to Alzheimer’s – and if so, whether this progress will be fast or slow.
“This has the potential to significantly improve patient wellbeing, showing us which people need closest care, while removing the anxiety for those patients we predict will remain stable. At a time of intense pressure on healthcare resources, this will also help remove the need for unnecessary invasive and costly diagnostic tests.”
While the researchers tested the algorithm on data from a research cohort, it was validated using independent data that included almost 900 individuals who attended memory clinics in the UK and Singapore. In the UK, patients were recruited through the Quantiative MRI in NHS Memory Clinics Study (QMIN-MC) led by study co-author Dr Timothy Rittman at Cambridge University Hospitals NHS Trust and Cambridgeshire and Peterborough NHS Foundation Trusts (CPFT).
The researchers say this shows it should be applicable in a real-world patient, clinical setting.
Dr Ben Underwood, Honorary Consultant Psychiatrist at CPFT and assistant professor at the Department of Psychiatry, University of Cambridge, said: “Memory problems are common as we get older. In clinic I see how uncertainty about whether these might be the first signs of dementia can cause a lot of worry for people and their families, as well as being frustrating for doctors who would much prefer to give definitive answers. The fact that we might be able to reduce this uncertainty with information we already have is exciting and is likely to become even more important as new treatments emerge.”
Professor Kourtzi said: “AI models are only as good as the data they are trained on. To make sure ours has the potential to be adopted in a healthcare setting, we trained and tested it on routinely-collected data not just from research cohorts, but from patients in actual memory clinics. This shows it will be generalisable to a real-world setting.”
The team now hope to extend their model to other forms of dementia, such as vascular dementia and frontotemporal dementia, and using different types of data, such as markers from blood tests.
Professor Kourtzi added: “If we’re going to tackle the growing health challenge presented by dementia, we will need better tools for identifying and intervening at the earliest possible stage. Our vision is to scale up our AI tool to help clinicians assign the right person at the right time to the right diagnostic and treatment pathway. Our tool can help match the right patients to clinical trials, accelerating new drug discovery for disease modifying treatments.”
This work was in collaboration with a cross-disciplinary team including Professor Peter Tino at the University of Birmingham and Professor Christopher Chen at the National University of Singapore. It was funded by Wellcome, the Royal Society, Alzheimer’s Research UK, the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator, the Alan Turing Institute, and the National Institute for Health and Care Research Cambridge Biomedical Research Centre.
Reference Lee, LY & Vaghari, D et al. Robust and interpretable AI-guided marker for early dementia prediction in real-world clinical settings. eClinMed; 12 July 2024; DOI: 10.1016/j.eclinm.2024.102725
Media enquiries.
Brain on molecular structure, circuitry, and programming code background
Credit: Yuichiro Chino (Getty Images)
Sign up to receive our weekly research email.
Our selection of the week's biggest Cambridge research news sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails and then select 'Subscribe'.
I wish to receive a weekly Cambridge research news summary by email.
The University of Cambridge will use your email address to send you our weekly research news email. We are committed to protecting your personal information and being transparent about what information we hold. Please read our email privacy notice for details.
© 2024 University of Cambridge
Call our 24 hours, seven days a week helpline at 800.272.3900
Brain donation.
New ideas study.
Let us connect you to professionals and support options near you. Please select an option below:
Use Current Location Use Map Selector
Invest in big, bold ideas with part the cloud.
Be part of an important effort to supercharge the development of genetic-based Alzheimer's therapies. Join the Gene Targeting Challenge.
This is a time of unprecedented promise in the quest to end alzheimer’s..
Today, we are growing philanthropic support for Alzheimer's research, fostering a dynamic community of Alzheimer's scientists and securing increased federal funding for research – all of which are instrumental to finding new treatments to stop, slow and prevent Alzheimer’s disease.
In the century since Alzheimer’s was first described, scientists have made remarkable strides in understanding the disease.
What if we could diagnose Alzheimer's before symptoms started? Research around earlier diagnosis is among the most active areas in Alzheimer's science.
While Alzheimer's prevention has no definitive answers yet, research has shown that we can take action to reduce our risk of developing it.
A donation today supports vital research toward methods of treatment, prevention and ultimately, a cure.
Both healthy brains and brains affected by diseases such as Alzheimer’s are needed to help advance dementia research. Learn about the donation process.
Don’t just hope for a cure, help us find one. Participating in a clinical trial, whether you’re living with the disease or not, can make a big difference.
The New IDEAS Study is designed to evaluate the use of PET scans in diverse populations living with dementia and Alzheimer's.
U.S. POINTER is a lifestyle intervention clinical trial to support brain health and prevent cognitive decline. Learn about study locations and eligibility.
The Alzheimer's Association is the world's largest nonprofit funder of Alzheimer's research, currently investing more than $405 million in over 1,100 active best-of-field projects in 56 countries, spanning six continents.
Our commitment to accelerating the global effort to eliminate Alzheimer's disease and other dementias is at the core of all we do.
Through our many initiatives and worldwide reach, the Alzheimer’s Association leads the charge in Alzheimer’s care, support, research and advocacy.
Discover how the Alzheimer’s Association connects scientists and fuels diverse research in an effort to change the trajectory of the disease.
The Alzheimer’s Association is an unrelenting advocate for public policies that increase critical research and support for all those affected.
The first survivor of alzheimer's is out there, but we won't get there without you., learn how alzheimer’s disease affects the brain..
Take the Brain Tour
share this!
July 11, 2024
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
by Washington University School of Medicine
Racial disparities in dementia are due to social determinants of health, with genetic ancestry playing no role, according to a new study led by researchers at Washington University School of Medicine in St. Louis.
The study, which was based on a long-running population-based survey in four Latin American countries, helps explain why people of predominantly Native American or African ancestry have a higher prevalence of dementia : Study participants were more likely to experience social contexts and health conditions that raised their risk of cognitive decline , such as lower education levels, rural residency and high blood pressure . Once such factors were accounted for, ancestry added no additional risk.
"Marginalized racial and ethnic groups have higher rates of dementia in many countries, and disentangling the biological from the social contributors has been challenging," said corresponding author Jorge Llibre-Guerra, MD, an assistant professor of neurology.
"Latin America provides a unique framework to separate the two. It is the region with the largest mixture of genetic ancestries, plus it has profound social inequalities. This study clearly shows that poor cognitive health is part of the legacy of the racial caste system. It's not family ancestry that is putting people at risk. In a way, the findings are reassuring, because social determinants of health are modifiable."
The study is published in the journal Alzheimer's & Dementia .
Once thought to be a natural and inevitable part of aging, cognitive decline and dementia increasingly have been recognized as products of a complex web of risk factors more likely to ensnare members of marginalized groups. In the U.S., for example, dementia is about twice as common in Black communities and 1½ times as common in Hispanic communities, compared with white populations.
What remains unclear is how much of the increased rate of dementia is due to modifiable risk factors linked to marginalization, such as education level and high blood pressure, and how much is due to genetic susceptibility associated with ancestry.
The first step in disentangling the roles of biological and social factors is to replace the complicated issue of racial and ethnic identity with the simpler matter of genetic ancestry. Race and ethnicity are not biological categories; they are defined by the cultures and societies in which people live, and the definitions vary by time and place. Genetic ancestry, on the other hand, is an objective measure of the proportion of an individual's DNA that can be traced back to one or more large areas of the globe—in this case, Africa, Europe or the Americas.
Llibre-Guerra and colleagues analyzed the relationship between genetic ancestry, social determinants of health, and cognitive function using survey data obtained by the 10/66 Dementia Research Group in Cuba, the Dominican Republic, Mexico and Peru.
The 10/66 group was established in 1998 to study the prevalence and impact of dementia in low- and middle-income countries by using population-based surveys that are internationally validated and standardized. The current study utilized data from the 10/66 group's first survey wave, conducted from 2004 to 2006. The first wave marks the beginning of systematic data collection across diverse settings and provides a critical benchmark for all subsequent analyses. The 10/66 group has since conducted two follow-up surveys and plans to continue expanding these assessments moving forward.
Eligible participants were found by trained surveyors who knocked on all doors in designated areas, a strategy designed to generate representative samples for each country. Each participant underwent an interview, physical examination, cognitive assessment and blood draw. In addition, surveyors interviewed a close relative or friend of each participant.
For the current study, the researchers analyzed deidentified data on 3,808 people ages 65 or older across the four countries. Individuals were categorized as predominantly of African, Native American or European ancestry if 70% or more of their DNA could be traced to the respective continent.
Each country had a unique mixture of ancestries. In Mexico and Peru, the greatest number of people were primarily of Native American heritage, followed by European and then African. In Cuba, most were of European ancestry, followed by African, with less than 3% Native American. In the Dominican Republic, most people were of African heritage, followed by European, with about 10% of Native American heritage.
The survey revealed that cognitive impairment was more common among older people of Native American or African ancestry than of European ancestry. While 47.8% of seniors of European heritage exhibited some degree of cognitive impairment, 52.7% of those with Native American ancestry and 54.9% of those with African ancestry showed such impairments. Once social and health factors such as education level, socio-economic status and cardiovascular health were taken into account, the association between genetic ancestry and cognitive performance disappeared.
"Our findings suggest that cognitive performance is largely influenced by upstream societal risk factors," the authors wrote in the study. "We found substantial disparities in social determinants of health among different ancestry groups in Latin America, stemming from enduring disadvantages and structural racism rooted in the colonial period."
The study findings echo what has been observed in the U.S., with marginalized groups experiencing higher rates of dementia and similar social inequities such as lower education attainment and reduced access to health care. "If we want to improve cognitive health for all people," Llibre-Guerra said, "we need to start by addressing these factors."
Explore further
Feedback to editors
12 hours ago
Jul 12, 2024
Related stories.
May 25, 2022
May 15, 2024
Dec 22, 2022
Apr 30, 2021
May 21, 2024
Nov 6, 2020
Jul 11, 2024
Jul 10, 2024
Jul 8, 2024
Jul 3, 2024
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form . For general feedback, use the public comments section below (please adhere to guidelines ).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.
More information Privacy policy
We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.
Here's how you know
Originally posted in FDA Press Announcements
The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Kisunla is administered as an intravenous infusion every four weeks. The recommended dosage is detailed in the prescribing information .
Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks. While the specific causes of Alzheimer’s are not fully known, it is characterized by changes in the brain—including amyloid beta plaques and neurofibrillary, or tau, tangles—that result in loss of neurons and their connections. These changes affect a person’s ability to remember, think and speak.
The efficacy of Kisunla was evaluated in a double-blind, placebo-controlled, parallel-group study (Study 1, NCT04437511) in patients with Alzheimer’s disease. The patients had confirmed presence of amyloid pathology and mild cognitive impairment or mild dementia stage of disease. 1736 patients were randomized 1:1 to receive 700 mg Kisunla every 4 weeks for the first 3 doses, and then 1400 mg every 4 weeks (N = 860) or placebo (N = 876) for a total of up to 72 weeks. The treatment was switched to placebo based on a prespecified reduction in amyloid levels measured by positron emission tomography (PET) at Week 24, Week 52, and Week 76.
Patients treated with Kisunla demonstrated a statistically significant reduction in clinical decline on the Integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo at Week 76 in the overall population (2.92, p<0.0001), as well as on the iADRS component scales, the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog13) (-1.33, p=0.0006) and the Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living (ADCS-iADL) scale (1.70, p=0.0001). Patients treated with Kisunla also demonstrated a statistically significant reduction in clinical decline on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) compared to placebo at Week 76 in the overall population (-0.70, p<0.0001).
At baseline, the study population had a mean age of 73 years, with a range of 59 to 86 years. Fifty-seven percent of patients were female, 91% were White, 6% were Asian, 4% were Hispanic or Latino, and 2% were Black or African American.
The prescribing information includes a boxed warning for amyloid-related imaging abnormalities (ARIA). ARIA most commonly presents as temporary swelling in areas of the brain that usually resolves over time and may be accompanied by small spots of bleeding in or on the surface of the brain. ARIA usually does not have symptoms, although serious and life-threatening events rarely can occur.
Patients who are APOE ε4 homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, compared to heterozygotes and noncarriers. Testing for APOE ε4 status should be performed prior to beginning treatment to inform the risk of developing ARIA.
There is risk of infusion-related reactions, with symptoms such as flu-like symptoms, nausea, vomiting and changes in blood pressure, and hypersensitivity reactions, including anaphylaxis (severe, life-threatening allergic reaction) and angioedema (swelling).
The most common side effects of Kisunla were ARIA and headache.
See full prescribing information (PDF, 664K) for additional information on risks associated with Kisunla.
The FDA granted this application Fast Track , Priority Review , and Breakthrough Therapy designations.
nia.nih.gov
An official website of the National Institutes of Health
TUESDAY, July 2, 2024 (HealthDay News) -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday.
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including swelling and bleeding in the brain.
"Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease, who urgently need effective treatment options. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis," Anne White , executive vice president and president of Lilly Neuroscience, said in a company news release announcing the approval. "Each year, more and more people are at risk for this disease, and we are determined to make life better for them."
Alzheimer's advocates applauded the approval.
"This approval marks another step forward in evolving the standard of care for people living with Alzheimer's disease that will ultimately include an arsenal of novel treatments, providing much needed hope to the Alzheimer's community," Dr. Howard Fillit , co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation, said in the Lilly news release. "Diagnosing and treating Alzheimer's sooner than we do today has the potential to meaningfully slow disease progression, giving patients invaluable time to maintain their independence for longer."
Kisunla is similar to another drug, Leqembi, approved to treat Alzheimer's last year. Both attack amyloid protein, which is involved in the development of Alzheimer’s, and both slowed dementia by several months. Leqembi is given every two weeks, while Kisunla is given monthly as an intravenous infusion.
Kisunla has another significant difference that will likely appeal to patients and doctors alike: The drug can be stopped once it clears all of the amyloid plaques from the brain.
“Once you’ve removed the target that you’re going after, you then can stop dosing,” said White, adding that this could cut the cost and inconvenience of the treatment as well as the risk of side effects.
In the company's trial, 17 percent of patients receiving donanemab were able to discontinue the drug at six months; 47 percent stopped within a year; and 69 percent stopped within 18 months. Importantly, their cognitive decline continued to slow even after they stopped.
Still, the treatment won't come cheap: The list price for Kisunla will be $32,000 a year. Leqembi costs $26,000 per year, but it is continued after all amyloid is cleared.
About one-fourth of those on donanemab experienced swelling or bleeding in the brain. While most of the cases were mild, roughly 2% were serious, and the side effects were linked to three patients' deaths.
With both drugs, patients at higher risk include those who have had more than four microscopic bleeds in the brain and those with an Alzheimer’s-linked gene variant called APOE4 — especially if they have two copies of the variant, the Times reported.
Some experts worry that emphasis on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better.
“For the field generally, I think this is moving sideways, and it’s slowing progress,” Dr. Michael Greicius , a neurologist at Stanford University School of Medicine, told the Times.
Dozens of other drugs are in clinical trials for Alzheimer’s, including drugs attacking important features like tau tangles and neuroinflammation, the Times reported.
More information
The Alzheimer's Association has more on Alzheimer's drugs .
SOURCES: U.S. Food and Drug Administration, news release, July 8, 2024; New York Times
Patients with Alzheimer's disease now have a new way to treat it. Kisunla is now approved by the U.S. Food and Drug Administration.
Alzheimer's disease is a progressive neurodegenerative disease that impairs memory and cognitive judgment and is often accompanied by mood swings, disorientation and eventually delirium.
Researchers have unveiled a pioneering study shedding light on the intricate mechanisms underlying Alzheimer's disease (AD).
Researchers call for a major rethink of how Alzheimer's treatments are evaluated An approach that aims to quantify how long a drug can delay or halt the progression of disease is gathering steam.
Alzheimer's disease (AD) is a polygenic multifactorial neurodegenerative disease that, after decades of research and development, is still without a cure. There are some symptomatic treatments to manage the psychological symptoms but none of these ...
Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial ...
The report features science advances and related efforts made between March 2021 and early 2022 in areas including drug development, lifestyle interventions, biomarker research, and more. It provides a comprehensive overview of the meaningful progress researchers are making to address the enormous health care challenges of Alzheimer's and related dementia diseases.
An estimated 50 million people worldwide have dementia, mostly due to Alzheimer's disease. The inexorable progression of Alzheimer's disease exerts a huge toll on patients, families, and ...
Leading the open access field for translational research into dementia and neurodegenerative diseases, Alzheimer's Research & Therapy is the major forum for ...
Alzheimer's is a complex disease, and as it slowly develops, many normal biological processes in the brain and the body go awry, from inflammation, to blood vessels damage and neuronal death. Seven recent AMP AD reports showcase research advances related to the discovery of new drug candidate targets, identification of molecular subtypes of the disease, and new potential biomarkers that can ...
Aims and scope. Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies.
Alzheimer's and dementia research - find the latest information on research funding, grants, clinical trials and global research news.
The Alzheimer's Disease Research Center studies the entire spectrum of aging, from normal aging to mild cognitive impairment to dementia in cooperation with the Mayo Clinic Study of Aging. The Mayo Clinic Study of Aging, one of the largest and longest running studies on aging, began in 2004 and has recruited more than 3,000 people.
BSR supports social and behavioral research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) in cognitive and dementia epidemiology, behavioral and social pathways to AD/ADRD, early psychological and functional changes, AD/ADRD prevention, dementia care, and caregiver/care partner research, health disparities, and research resources.
Innovative research from Mount Sinai has also identified new pathways for research. Researchers at the Icahn School of Medicine at Mount Sinai have achieved a major breakthrough in Alzheimer's disease research. Their study identifies a promising method that could potentially slow or even stop the progression of the disease. Focusing on the role of reactive astrocytes and the plexin-B1 ...
The Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease brings experts together to practice precision medicine for personalized Alzheimer's health. Learn more about our research.
Learn about the diverse research areas the federal government and others are exploring to improve quality of life for people with Alzheimer's disease and related dementias and to prevent and treat these diseases.
An innovative journal dedicated to accelerating significant research and clinical developments to advance progress in combating the physical, social and financial impacts of dementia.
Dementia is a general term that refers to memory loss and decline of other cognitive abilities that limit independence in day-to-day function. Alzheimer's is the most common brain disease that causes dementia among older adults, accounting for 60%-80% of cases. It affects an estimated one in nine people age 65 and older — 6.2 million ...
Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) refers to the most common forms of dementia. Dementia likely affects more than 6 million people in the U.S. and more than 55 million people worldwide.
Topics. Conditions. Week's top; ... able to predict whether and how fast an individual with mild memory and thinking problems will progress to developing Alzheimer's disease. In research published ...
The prize recognizes the senior and first authors of a recent scientific publication that transforms the fundamental understanding of Alzheimer's disease and opens new paths to translate scientific results into effective ways to prevent, diagnose or treat the neurodegenerative condition. Read more on the School of Medicine website.
Ten million new cases of dementia are diagnosed each year but the presence of different dementia forms and overlapping symptoms can complicate diagnosis and delivery of effective treatments. Now ...
A team led by scientists from the Department of Psychology at the University of Cambridge has developed a machine learning model able to predict whether and how fast an individual with mild memory and thinking problems will progress to developing Alzheimer's disease. In research published today in eClinical Medicine, they show that it is more ...
This is a time of unprecedented promise in the quest to end Alzheimer's. Today, we are growing philanthropic support for Alzheimer's research, fostering a dynamic community of Alzheimer's scientists and securing increased federal funding for research - all of which are instrumental to finding new treatments to stop, slow and prevent Alzheimer's disease.
Our Director of Research responds to news that the FDA has approved new Alzheimer's disease drug donanemab in the US.
3 hot topics in dementia research right now Today there are more dedicated dementia researchers working to understand the condition and develop new treatments than ever before. Our research team went to the Alzheimer's Association International Conference (AAIC) in Los Angeles to get all the latest news.
Racial disparities in dementia are due to social determinants of health, with genetic ancestry playing no role, according to a new study led by researchers at Washington University School of ...
With a second pricey drug to treat Alzheimer's disease set to receive an approval decision soon, the nonprofit Alzheimer's Association has published the final version of its new diagnostic ...
The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
TUESDAY, July 2, 2024 (HealthDay News) -- A new drug to treat Alzheimer's disease was approved by the U.S. Food and Drug Administration on Tuesday.. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease.
Federal Board, FBISE Class 9 Pak Studies Chapter 3 MCQs Test is available on this page. Chapter-wise MCQs Tests of Pak Studies are also available on our website.
Class 9 Pak Studies Chapter 3 Exercise Practice MCQs Test
1. The ______ mountain range makes the boundary line between Pakistan and Afghanistan.
2. The Muslim Bagh and Ziarat hills are situated in the _______ plateau.
3. At one point near Sakesar, the Salt range rises to the height of ______ meter from the sea level.
4. Only ______ percent of the Pakistan area is covered with forests.
5. The border line between Pakistan and China is ______ km long.
6. K2 is the _____ highest mountain in the world.
7. Sibbi and _______ are among the hottest places on the earth.
8. The coastal line of Pakistan is ______ km long.
9. The national bird of Pakistan is _______.
10. The total area of Pakistan is _________ Square km.
11. Murree and Hazara Hills are part of the _______ Mountain range.
12. The only continent in the world so far immunes from deforestation is _______.
13. The THAL desert is situated in the _________ province of Pakistan.
14. Durand Line is _________ km long.
15. The river Indus originates from lake _______.
Your score is
Restart quiz
Please rate this quiz and give your feedback.
Chemistry 9 chapter 1 practice test 2.
Chemistry 9 Chapter 1 Practice Test 2 See also Class 9 Computer Science Model Paper 2 MCQs Test
In this post, we have prepared 3 MCQs tests of Federal Board Physics 9 Unit 4 MCQs Tests. Class 9 => ( Physics Notes | Model Papers | Past Papers | Solved Papers | Solved MCQs ) Physics 9 Unit 4 MCQs Tests Practice MCQs Test No 1 Practice MCQs Test No 2 Challenge MCQs…
In Chemistry 9 Chapter 6 MCQs Test 2, there are 13 MCQs. We have prepared 25 multiple-choice questions, which are divided into 2 practice Tests and two Test yourself MCQs Tests. All MCQs are prepared from FBISE Book and Past Papers. Practice MCQs Test No 2 We have also made a test yourself MCQs Test…
Federal Board, FBISE Class 9 Pak Studies Chapter 2 MCQs Test is available on this page. Chapter-wise MCQs Tests of Pak Studies are also available on our website. Class 9 Pak Studies Chapter 2 Exercise MCQs Test See also Biology 9 Chapter 6 Practice Test 1
Chemistry 9 Chapter 3 Practice Test 2 See also Computer Science 9 Chapter 6 MCQs Test 1
FBISE Federal Board English 9 Model Paper 2 MCQs Test. Do as much practice as you can so that you get good marks in the final exams. Class 9 English Model Paper 2 MCQs Test See also English 9 Sultan Ahmad Mosque MCQs Test
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Advertisement
Supported by
Unrest over a range of economic and security issues threatens to deepen the political turmoil that has plagued Pakistan for years.
By Christina Goldbaum and Salman Masood
Christina Goldbaum reported from London, and Salman Masood from Islamabad, Pakistan.
In almost every corner of Pakistan, anger at the ruling elite is nearing a boiling point.
Thousands have protested soaring electricity bills just outside the capital, Islamabad. In a major port city in the southwest, dozens have clashed with security officers over what they described as forced disappearances of activists. In the northwest, protesters have admonished the country’s generals for a recent surge in terrorist attacks.
The demonstrations over the past few weeks reflect frustration with Pakistan’s shaky, five-month-old government and with its military, the country’s ultimate authority. The unrest threatens to plunge Pakistan back into the depths of political turmoil that has flared in recent years and that many had hoped would subside after the February general election.
Pakistan’s leaders are confronted with a monsoon of problems. The economy is suffering its worst crisis in decades . Anger at an election widely viewed as manipulated by the military remains palpable. Militant violence has roared back after the Taliban’s return to power in neighboring Afghanistan. And Pakistani politics are more polarized than ever, with the country’s most popular political figure sitting in jail after a bitter rift with the military.
The administration of the current prime minister, Shehbaz Sharif, has struggled to establish its legitimacy and has been criticized as little more than a front for the military.
Since Mr. Sharif first came into office in 2022, Pakistan’s generals have wielded an increasingly heavy hand to quash dissent. A national firewall has been installed to censor internet content, the social media platform X has been blocked, security forces have arrested political opponents in droves, and generals have been installed in key positions in the civilian government.
We are having trouble retrieving the article content.
Please enable JavaScript in your browser settings.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in .
Want all of The Times? Subscribe .
At least 46 people were killed and 200 injured in clashes until a temporary ceasefire was agreed upon on Wednesday.
Islamabad, Pakistan – After weeklong clashes between rival tribes in Pakistan’s district of Kurram, killing at least 46 people and injuring nearly 200, fighting has now halted, following a meeting between authorities and tribal elders.
A grand jirga, or a gathering of tribal elders, along with civilian and security officials, met in Parachinar, the main city in Kurram district. They held an hours-long meeting on Wednesday, after which a ceasefire was agreed upon by all stakeholders – until October 5.
Roadside bomb kills several in northwest pakistan, a community under siege, several teachers killed in pakistan school shooting.
Javedullah Mehsud, the deputy commissioner of Kurram, said there had been no casualties since then and that the government was confident of reaching a resolution to end the conflict.
“This is unfortunately an ongoing land dispute in the area that has led to fighting in the past as well, but we are confident that we can put an end to it this time,” Mehsud told Al Jazeera.
So where is Kurram, what happened there, how did things escalate and what’s next?
Kurram, a mountainous area that shares a long border with Afghanistan in the northwestern province of Khyber Pakhtunkhwa, is home to about 700,000 people, of which more than 42 percent belong to the Shia community.
It is closer to Afghanistan’s capital Kabul than any major city in Pakistan but also borders Afghanistan’s Khost, Paktia, Logar and Nangarhar provinces, which are considered havens for anti-Shia armed groups such as ISIL (ISIS) and the Pakistan Taliban (TTP).
The area has a history of sectarian conflict between the Shia and the Sunni majority groups and has also faced militancy during the past decade, with frequent attacks by TTP and other armed groups targeting the Shia community.
According to local authorities and tribal leaders, the current conflict has its roots in a continuing land dispute between Shia-majority and Sunni-majority tribes. Another similar incident flared up last year, resulting in the deaths of at least 20 people.
The Human Rights Commission of Pakistan (HRCP) urged the government to help broker peace in the area where, it added, “violence has taken a heavy toll on ordinary citizens”.
“HRCP calls on the KP government to ensure that the ceasefire being brokered, holds. All disputes, whether over land or born of sectarian conflict, must be resolved peacefully through negotiations convened by the KP government with all stakeholders represented,” it said in a statement on July 29.
HRCP is deeply concerned at the significant loss of life in #Parachinar , Kurram, where rival tribes have engaged in a violent land dispute for several days, fueling sectarian conflict. The violence has taken a heavy toll on ordinary citizens, whose freedom of movement and access… — Human Rights Commission of Pakistan (@HRCP87) July 29, 2024
Mehmood Ali Jan, a member of the local peace committee and part of the jirga that held meetings this week, says that the conflict arose between Maleekhel, a Shia-majority tribe, and Madgi Kalay, a Sunni-majority tribe, over a tract of land in Boshehra village, situated 15km (9 miles) south of Parachinar city.
“It was a piece of agricultural land originally owned by the Shia tribe, which they had leased to the Sunni tribe for farming purposes. The lease was supposed to end this July, but when the time came, they refused to return the land, leading to fighting,” Jan told Al Jazeera.
Jan says that the local peace committee, which included members from both Shia and Sunni tribes, immediately tried to pacify the situation and asked the government to intervene. But the government, he says, was late to respond.
“The state was completely absent initially, leading to so much fighting. They did not interfere or send in forces or police despite the heavy presence of military and paramilitary personnel in the area,” Jan claimed.
Nisar Ahmad Khan, the district police officer, however, refutes the allegations of government inaction, saying that as soon as the fighting began, the state took swift action. He conceded, however, that a lack of manpower and the difficult terrain impeded the pace of the government’s response.
“We have limited capacity, and Kurram is a large, difficult area to access due to its mountainous terrain. Often, we had to hike for hours to reach places where fighting was taking place. Plus, due to the porous border with Afghanistan, many people have access to sophisticated weapons, making it even more difficult,” the police officer told Al Jazeera.
However, he categorically denied any involvement of TTP or any other armed group targeting the Shia community for their religious identity.
“The Boshehra village, where most of the fighting took place, has a strategic advantage for defenders, and anyone who tried to gain access was easily targeted. In this case, it was the Maleekhel tribe, which suffered more losses,” he said.
Jan, the tribal elder, said even though a land dispute is at the heart of the current tensions, the region’s long history of sectarian strife allows “some elements” from both sides to use religion as a tool to mobilise.
“There have been major land dispute conflicts in the Kurram area between various tribes that have been ongoing since before the partition [of the Indian subcontinent in 1947]. Whenever anything triggers, it is conveniently given a sectarian angle, which is not the case,” he added.
There have been several incidents of significant sectarian violence in the last seven decades, but the most serious clash started in 2007, in which fighting between Shia and Sunni tribes lasted for almost four years. Several villages were set ablaze and thousands of people had to leave the region and seek shelter in other parts of the country.
Kurram, which was at the time part of the Federally Administered Tribal Areas (FATA), was cut off from the rest of the country. In 2011, the Pakistani military, with the help of local tribal elders, finally managed to put an end to the fighting. Government data shows nearly 2,000 people were killed in the clashes, while more than 5,000 people were reported injured.
Khan, the police chief said that in many areas of the district, Shia and Sunni communities live together peacefully.
He cited the Ashura procession last month, marked to mourn the martyrdom of Husayn Ibn Ali al-Hussein, the grandson of Prophet Muhammad.
“We recently had the Ashura processions, which were taken out in different parts of Kurram. In many areas, Sunni tribes provided security for Shias who were mourning,” Khan said.
Mehsud, the deputy commissioner, said the government hoped to use the ceasefire to resolve the land dispute between the Maleekhel and Madgi Kalay tribes.
“We have our land dispute resolution mechanisms, and this ceasefire will allow us to bring all stakeholders together to try to end this permanently,” he said.
The fighting led to the closure of most roads leading to Kurram, and news reports emerged that even ambulances were targeted by unknown men.
Schools in Parachinar remained closed, while markets saw little activity. Jan, who is also a trader, said the closure of roads led to shortages of food and other necessary items, making it difficult for anyone needing to leave town in case of an emergency.
“After the ceasefire, we are hoping that life returns to normal. Right now, people are travelling in convoys only, with police and paramilitary forces guarding the roads leading out of Kurram,” he said.
Jan also added that the fighting resulted in the closure of the mobile data network, but fixed lines were working.
Mehsud, the government official, said that after the pause in fighting, there is an uneasy calm in the area but he expressed hope that normal activity in the region should resume soon.
“Naturally, there is an air of fear right now, and people are reluctant to step out of their homes. However, in the last two days, we have seen some semblance of normalcy, and things should improve,” he said.
IMAGES
VIDEO
COMMENTS
As a result, it becomes an indispensable study tool. Social Science Case Study Questions The need for a student-friendly app to explain and facilitate the understanding of the social sciences subject has been felt for a long. Especially for students who do not have a strong foundation in Class 9 Social Science.
Get access to the latest Pakistan: A Case Study prepared with CBSE Class 9 course curated by Sarbani Chowdhury on Unacademy to prepare for the toughest competitive exam.
9th Class Pak Study Chapter No.1 Ideological Basis of Pakistan Urdu and English Notes. Definition of Ideology: Ideology refers to a set of beliefs, values, ideas, and principles that form the foundation of a political, social, or economic system. It is a comprehensive worldview that guides individuals or groups in understanding and interpreting ...
#tutoriadotpk #pakistanstudies #makingofpakistanLearn Class 9th Complete Chapter 2 Making of Pakistan!This lecture entails how Pakistan came into being, Paki...
Browse through the CBSE Notes Class 9 Political Science Chapter 1-What is Democracy? Why Democracy? and revise the entire chapter for the exam. This is the best way to understand all the concepts and prepare for the exam.
Learn class 9 Pakistan Studies effectively with our complete chapter 1 crash course! This lecture entails the complete chapter one Ideology of Pakistan by Quaid-e-Azam, including sources of ...
The basis of the Foundation of Pakistan: The basis of the ideology of Pakistan lies in the religion of Islam which guides the Muslims in every sphere of life. Islamic way of living encompasses all aspects of human life. It has a basic principle concerning social, moral, political, religious and economic fields.
#tutoriadotpk #pakistanstudies #historyofpakistanLearn Class 9th Complete Chapter 4 History of Pakistan!This lecture entails the complete chapter of History ...
Download Class 9 Civics Chapter 1 Notes - What is Democracy? Why Democracy? PDF for free. Secure good marks by referring NCERT notes prepared by Vedantu experts.
Read the source given below and answer the questions that follow: In Pakistan, General Pervez Musharraf led a military coup in October 1999. He overthrew a democratically elected government and declared himself the 'Chief Executive' of the country. Later he changed his designation to President and in 2002 held a referendum in the country ...
Chapter 1 of the 9th class notes covers the ideological basis of Pakistan, which is the vision of a separate homeland for the Muslims of India. The chapter explains the historical, religious, cultural, and political factors that led to the demand for Pakistan.
Case Study Questions for Class 9 Social Science Geography Chapter 2 What is Democracy Why Democracy Case Study Questions Question 1: Read the following passage and answer the questions that follows: In Pakistan, General Pervez Musharraf led a military coup in October 1999.
Class 9 Social Science Civics Chapter 1 What is Democracy Why Democracy extra questions and answers available here in PDF format. Solving class 9 extra questions help students to revise the Chapter most competently.
Dear Students, Respectable Teachers and Parents, In 9th Class Pakistan Studies, the 1st Chapter is Ideological Basis of Pakistan. In this chapter the students will learn about the Importance of Pakistan Studies as a subject which can help in understanding the origin, creation and development of Pakistan. Definition and Significance of Ideology for a Nation. The […]
#tutoriadotpk #pakistanstudey #pakistanmovementandemergenceofpakistanLearn the complete Pakistan Movement and the Emergence of Pakistan class 9 here! In this...
Class IX Pakistan Studies Notes Class 9 Pakistan Studies notes according to FBISE syllabus. Contains solved exercises, review questions, important MCQs, important board questions and chapter overview.
Download Class 9 Pakistan Studies Notes for both Urdu and English Medium Arts/Science Group Students 2024-25 of FBISE & Punjab Boards.
Pak Studies Class 9th Objective (2021) (1) M.A. school and college was established by: (A) Sir Syed Ahmad Khan (B) Chaudhry Rahmat Ali (C) Qazi Isa (D) Mauivi Fazal-ul-Haq (2) The ideology of Pakistan…
Civil-Military Relations: A Case Study of Pakistan. by. Najiyah Khan. Dr. Mehran Tamadonfar, Examination Committee Chair Associate Professor of Political Science University of Nevada, Las Vegas. Pakistan is a young and violent nation. It has been under military rule for.
myCBSEguide. Social Science; Class 9 Social Science... Class 9 Social Science Case Study Questions. Table of Contents. myCBSEguide App. Download the app to get CBSE Sample Papers
Federal Board, FBISE Class 9 Pak Studies Chapter 3 MCQs Test is available on this page. Chapter-wise MCQs Tests of Pak Studies are also available on our website.
Unrest over a range of economic and security issues threatens to deepen the political turmoil that has plagued Pakistan for years.
Kurram clashes: How a Pakistani land dispute led to a deadly tribal battle. At least 46 people were killed and 200 injured in clashes until a temporary ceasefire was agreed upon on Wednesday.